Using a mathematical model we showed that a non-overlappling adminstration of the two drugs is more effective in reducing tumor volume than simultaneous administration of the drugs in the case where anti-VEGF degrades perfusion, as it occurs in some cancers, while the opposite is true when perfusion is enhanced by anti-VEGF. This evidence concerns the gene VEGFA and cancer.